

LETTER TO THE EDITOR

COMMERCIALY AVAILABLE ANTI-S-100 PROTEIN SERUM STAINS *M. LEPRAE* IN
LEPROSY TISSUES BY IMMUNOHISTOCHEMICAL PROCEDURES.

Demonstration of bacilli and consequently of their antigenic products is easily feasible in multibacillary (LL, BL, BB) forms of leprosy. However, the presence of a non specific chronic inflammatory infiltrate, as seen in indeterminate leprosy, or the persistence of a granuloma in the paucibacillary (BT, TT) forms of leprosy in the absence of demonstrable bacilli, may indicate that free antigenic products are initiating the apparently non-specific inflammation and/or perpetuating the granuloma (9).

Immunohistochemistry proved to be useful to demonstrate infectious organisms and/or their antigens in tissues. Antigenic analysis indicates that there are common antigenic sites among mycobacterial species. On this basis rabbit anti-BCG serum has been widely used as the primary antibody to demonstrate both the bacilli and their antigens in leprosy tissues (5,6). Recently monoclonal antibodies against *M. leprae* have been produced which recognise specific antigens on cell surfaces of leprosy lesions (8).

A phenolic glycolipid with a structure related to mycoside A of *Mycobacterium kansasii* was found in *M. leprae* preparation and had its structure elucidated by HUNTER & BRENNAN (3) and HUNTER, FUJIWARA & BRENNAN (4). A highly specific trisaccharide for serodiagnosis of leprosy was synthesized and proved to be highly sensitive in ELISA (1). This synthetic trisaccharide (ST) is antigenic and anti-serum against it was raised in rabbits by a standard procedure, using incomplete Freund's adjuvant, and was used as primary antibody in an avidin-biotin peroxidase immunohistochemical reaction by us. In multibacillary leprosy, bacilli and/or their antigens were heavily stained in essentially similar manner by anti-BCG and anti-ST sera. In paucibacillary leprosy isolated macrophages in the granuloma were stained by both anti-sera, probably indicating antigenic products which might be relevant in the perpetuation of the granulomatous inflammation.

S-100 is an acidic calcium binding protein so-named because of its solubility in 100% ammonium sulphate solution at neutral pH; it is distributed in the brain of a wide variety of species and is regarded as species non-specific (7). The finding of S-100 antigen in non-nervous tissues and, particularly in antigen-presenting cells of the skin in normal conditions, suggests that S-100 should no longer be considered strictly as a nervous system specific protein. In paucibacillary leprosy S-100 antigen detection was used as a marker to cutaneous nerve branches, since dermal nerves impairment by inflammatory reaction permits the differential diagnosis between paucibacillary leprosy and other skin granulomatosis (2).

A positive staining of *Mycobacterium leprae* and/or its antigens with commercially available (DAKO, Denmark) polyclonal anti S-100 rabbit serum was detected by us in multibacillary leprosy. Essentially similar antigenic sites were demonstrated by S-100, anti BCG and anti ST sera. Lepromin absorbed anti S-100 serum failed to stain bacilli but maintained its staining properties as far as antigen presenting cells and dermal nervous branches were concerned. Therefore, the use of non-specifically absorbed commercial anti S-100 protein polyclonal serum in paucibacillary leprosy stains structures known to be usually stained by this anti-serum together with bacillary antigens. The staining properties of *M. leprae* by commercially available (DAKO) polyclonal anti S-100 protein serum is really an artefact. This anti-serum is raised in rabbits using complete Freund's adjuvant, which contain mycobacteria. Consequently different antibodies are present in the anti-serum, some recognizing *M. leprae* and others recognizing S-100 protein.

Therefore, care should be taken when using in immunohistochemical procedures commercially available anti-serum in infectious diseases, chiefly in countries where tuberculosis and leprosy are endemic.

REFERENCES

1. CHO, S.N.; FUJIWARA, T.; HUNTER, S.W.; REA, T.H.; GELBER, R.H. & BRENNAN, P.J. – Use of an artificial antigen containing the 3,6-di-0-methyl-D-glucopyranosyl epitope for the serodiagnosis of leprosy. *J. infect. Dis.*, 150:311-322, 1984.
2. FLEURY, R. & BACCHI, C.E. – S-100 protein and immunoperoxidase technique as an aid in the histopathologic diagnosis of leprosy. *Int. J. Leprosy*, 55:338-344, 1987.
3. HUNTER, S.W. & BRENNAN, P. – A novel phenolic glycolipid from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. *J. Bact.*, 147:728-735, 1981.
4. HUNTER, S.W.; FUJIWARA, T. & BRENNAN, P.J. – Structure and antigenicity of the major specific glycolipid antigen of *Mycobacterium leprae*. *J. biol. Chem.*, 257:15072-15078, 1982.
5. MSHANA, R.N.; BELEHU, A.; STONER, G.L.; HARBOE, M. & HAREGEWOIN, A. – Demonstration of mycobacterial antigens in leprosy tissues. *Int. J. Leprosy*, 50:1-10, 1982.
6. MSHANA, R.N.; HUMBER, D.P.; BELEHU, A. & HARBOE, M. – Immunohistological studies of skin biopsies from patients with lepromatous leprosy. *J. clin. Immunol.*, 3:22-29, 1983.
7. NAKAJIMA, T.; WATANABE, S.; SATO, Y.; KAMEYA, T.; HIROTA, T. & SHIMOSATO, Y. – An immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissues. *Amer. J. Surg. Path.*, 6:716-727, 1982.
8. NARAYANAN, R.B.; RAMU, G.; SINHA, S.; SENZUPTA, U.; MALAVIYA, G.N. & DESIKAN, K.V. – Demonstration of *Mycobacterium leprae* specific antigens in leprosy lesions using monoclonal antibodies. *Indian J. Leprosy*, 57:258-264, 1985.
9. RIDLEY, D.S. – Histological classification and the immunological spectrum of leprosy. *Bull. Wld. Hlth Org.*, 51:451-465, 1974.

“Instituto Adolfo Lutz”, S. Paulo Health Service and Institute of Tropical Medicine, USP.

S.A.C. Siqueira
A. Wakamatsu
V.A.F. Alves
T. De Brito

Recebido para publicação em 22/2/1990.